title: Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
abstract: The unbound concentration in plasma drives the transport of the drug into the brain, and the unbound drug concentration in the central nervous system (CNS) drives the interaction with the target eliciting the pharmacological effect. Delivery of the drug to the CNS is a challenge because of the unique neurovascular unit, which restricts the passage of drugs into the brain. The efflux transporters [especially P-glycoprotein (P-gp)] present at the blood-brain barrier (BBB) act as one of the major detractors for keeping drugs outside the CNS. The cerebrospinal fluid (CSF) drug concentration has been used as a surrogate for unbound brain concentrations and has proven to be a good indicator to relate to CNS activity. Herein, we have established a serial CSF sampling technique in rats, which allowed CSF sampling from a single animal and reduced the number of animals required, as well as the interanimal variance associated with a composite/terminal study design. Concentrations in the CSF sampled from the cisterna magna serially from the same rat were compared with the concentrations obtained from discrete CSF sampling and with brain concentrations. The serial CSF sampling technique was also authenticated by ensuring no change in the barrier without any indication of damage caused by the repeated puncture of cisterna magna. This technique was corroborated using three passively permeable compounds (carbamazepine, theophylline, and propranolol), three P-gp substrates (quinidine, verapamil, and digoxin), and one l-amino acid uptake transporter substrate (gabapentin). The P-gp substrates were also used in separate studies with the P-gp inhibitor elacridar to assess the effect on CSF concentration versus brain concentration on P-gp inhibition. The CSF concentration and unbound brain concentration were comparable (within 3-fold) for all compounds, including P-gp substrates even in the presence of elacridar. Therefore, this technique can prove to be beneficial for predicting the unbound drug concentrations in the brain from the CSF concentrations and reduce the cost incurred in preclinical animal models. Chemical inhibition by elacridar and prediction of the brain unbound concentrations from the serial CSF sampling of P-gp substrates in the rat may be an attractive alternative to the use of genetically knocked out rodents.
authors.affiliation: Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd. , Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560 099, India.
authors.forename: T Thanga
authors.initials: TT
authors.lastname: Mariappan
authors.forename: Vishwanath
authors.initials: V
authors.lastname: Kurawattimath
authors.forename: Shashyendra Singh
authors.initials: SS
authors.lastname: Gautam
authors.forename: Chetan P
authors.initials: CP
authors.lastname: Kulkarni
authors.forename: Rajareddy
authors.initials: R
authors.lastname: Kallem
authors.forename: Kunal S
authors.initials: KS
authors.lastname: Taskar
authors.forename: Punit H
authors.initials: PH
authors.lastname: Marathe
authors.forename: Sandhya
authors.initials: S
authors.lastname: Mandlekar
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000097:blood / Q000134:cerebrospinal fluid* / Q000737:chemistry; D000818:Animals; D001692:Biological Transport; D001812:Blood-Brain Barrier / Q000378:metabolism; D001923:Brain Chemistry; D002555:Cerebrospinal Fluid / Q000737:chemistry; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis*; D057230:Limit of Detection; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D002556:Cerebrospinal Fluid Proteins